AutoresBorja Quiroga, María José Soler, Alberto Ortíz, Amparo Bernat, Ana Beatriz Muñoz Díaz, Carlos Jesús Jarava Mantecón, Virginia Olinda Gómez Pérez, Carmen Calderón González, Michal Červienka, Auxiliadora Mazuecos, Juan Manuel Cazorla, Manuel Carnerero Di Riso, Shaira Martínez, Mayra Ortega Díaz, Rafael Lucena Valverde, Marı́a Gabriela Márquez, Carolina Lancho Novillo, Emilio González Parra, Carolina Gracia-Iguacel, María Teresa Rodrigo De Tomas, María Cinta Aguilar Cervera, Martín Giorgi, Patricia Muñoz Ramos, Nicolás Macías Carmona, Néstor Toapanta, Secundino Cigarrán Guldris, Juan Carlos Ruiz, Raquel Santana Estupiñán, Marta Crespo, Blanca Villacorta Linaza, María Isabel Jimeno Martín, Laura Rodríguez-Osorio Jiménez, Sagrario Soriano, Dioné González Ferri, Maria Soledad Pizarro-Sánchez, Alejandra Yugueros González, Alba Leyva, José Antonio Muñoz Rojas, Ron T. Gansevoort, Patricia de Sequera, The SENCOVAC collaborative network, Marta Puerta Carretero, Daniel Gaitán Tocora, Ma Teresa Jal
SENCOVAC is a prospective multicentric study promoted by the Spanish Society of Nephrology (S.E.N.), which included four cohorts of adults with chronic kidney disease (CKD): kidney transplant recipients (KTRs), haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis (ND)-CKD patients [glomerular filtration rate (GFR) <30 mL/min/1.73 m2] [1]. Participants were immunized with locally available vaccines [BNT162b2 (Pfizer-BioNTech®), mRNA-1273 (Moderna®), ChAdOx1-S (AstraZeneca®) or Ad26.COV.2 (Janssen®)] prescribed by regional health authorities unrelated to the study investigators. The present analysis (20 September 2021) predates booster doses. The primary objective was seroconversion after vaccination. Preliminary data showed lower anti-Spike antibody development after vaccination in KTRs than in other CKD patients [1] (Supplementary Material and methods). SENCOVAC included 3439 patients and analysed 28-day humoral immunity in 1061 patients and 3-month humoral immunity in 567 patients. Baseline characteristics of patients analysed 28 days and 3 months after vaccine completion are summarized in Supplementary data, Tables S1 and S2. At 28 days, 255 (24%) were KT, 103 (10%) PD, 610 (57%) HD and 93 (9%) ND-CKD patients (Figure 1A). At 3 months, 155 were KT (27%), 28 (5%) PD, 332 (59%) HD and 52 (9%) ND-CKD patients (Figure 1A). (A) Flow chart of the SENCOVAC study. (B) Proportion of patients with positive humoral response at baseline, 28 days and 3 months. (C) Negative and equivocal humoral response 3 months after completing vaccine schedule among patients with positive humoral response at 28 days. Data expressed as percentage of those who were positive at 28 days. (A) Flow chart of the SENCOVAC study. (B) Proportion of patients with positive humoral response at baseline, 28 days and 3 months. (C) Negative and equivocal humoral response 3 months after completing vaccine schedule among patients with positive humoral response at 28 days. Data expressed as percentage
